[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571099":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":85,"centralContacts":90,"locations":101,"responsibleParty":118,"collaborators":95,"id":120,"slug":95,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":95,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":127,"maxAge":128,"enrollmentInfo":129,"targetDuration":95,"studyType":132,"phases":133,"briefSummary":135,"conditions":136,"keywords":152,"overallStatus":104,"whyStopped":95,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":167},{"fullName":5,"class":6},"RenJi Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ImmunoPET imaging in patients with digestive system carcinoma","EXPERIMENTAL","Enrolled patients will undergo a targeted-specific immunoPET\u002FCT scanning.",[13,14,15,16,17,18,19,20,21,22],"Drug: [68Ga]Ga-DOTA-H2D3","Drug: [18F]F-RESCA-RB14","Drug: [68Ga]Ga-NOTA-T4","Drug: [18F]F-RESCA-T4","Drug: [68Ga]Ga-NOTA-G5","Drug: [18F]F-RESCA-G5","Drug: [68Ga]Ga-NOTA-WWH347","Drug: [18F]F-RESCA-WWH347","Drug: [68Ga]Ga-NOTA-RND20","Drug: [18F]F-RESCA-RND20",[24,31,37,43,49,55,61,67,73,79],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","[68Ga]Ga-DOTA-H2D3","Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi\u002Fkg of a HER2-targeted probe (\\[68Ga\\]Ga-DOTA-H2D3). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-DOTA-H2D3 injection.",[9],[30],"[68Ga]Ga-H2D3",{"type":25,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"[18F]F-RESCA-RB14","Enrolled patients (especially those with gastric cancer) will receive 0.05-0.1 mCi\u002Fkg of a HER2-targeted probe (\\[18F\\]F-RESCA-RB14). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RB14 injection.",[9],[36],"[18F]F-RB14",{"type":25,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"[68Ga]Ga-NOTA-T4","Enrolled patients (especially those with gastric cancer\u002Fpancreatic cancer) will receive 0.05-0.1 mCi\u002Fkg of a Trop2-targeted probe (\\[68Ga\\]Ga-NOTA-T4). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-T4 injection.",[9],[42],"[68Ga]Ga-T4",{"type":25,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"[18F]F-RESCA-T4","Enrolled patients (especially those with gastric cancer\u002Fpancreatic cancer) will receive 0.05-0.1 mCi\u002Fkg of a Trop2-targeted probe (\\[18F\\]F-RESCA-T4). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-T4 injection.",[9],[48],"[18F]F-T4",{"type":25,"name":50,"description":51,"armGroupLabels":52,"otherNames":53},"[68Ga]Ga-NOTA-G5","Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi\u002Fkg of a GPC3-targeted probe (\\[68Ga\\]Ga-NOTA-G5). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-G5 injection.",[9],[54],"[68Ga]Ga-G5",{"type":25,"name":56,"description":57,"armGroupLabels":58,"otherNames":59},"[18F]F-RESCA-G5","Enrolled patients (especially those with hepatocellular carcinoma) will receive 0.05-0.1 mCi\u002Fkg of a GPC3-targeted probe (\\[18F\\]F-RESCA-G5). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-G5 injection.",[9],[60],"[18F]F-G5",{"type":25,"name":62,"description":63,"armGroupLabels":64,"otherNames":65},"[68Ga]Ga-NOTA-WWH347","Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi\u002Fkg of a GPA33-targeted probe (\\[68Ga\\]Ga-NOTA-WWH347). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-WWH347 injection.",[9],[66],"[68Ga]Ga-WWH347",{"type":25,"name":68,"description":69,"armGroupLabels":70,"otherNames":71},"[18F]F-RESCA-WWH347","Enrolled patients (especially those with colorectal cancer) will receive 0.05-0.1 mCi\u002Fkg of a GPA33-targeted probe (\\[18F\\]F-RESCA-WWH347). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-WWH347 injection.",[9],[72],"[18F]F-WWH347",{"type":25,"name":74,"description":75,"armGroupLabels":76,"otherNames":77},"[68Ga]Ga-NOTA-RND20","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of a Nectin-4-targeted probe (\\[68Ga\\]Ga-NOTA-RND20). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[68Ga\\]Ga-NOTA-RND20 injection.",[9],[78],"[68Ga]Ga-RND20",{"type":25,"name":80,"description":81,"armGroupLabels":82,"otherNames":83},"[18F]F-RESCA-RND20","Enrolled patients will receive 0.05-0.1 mCi\u002Fkg of a Nectin-4-targeted probe (\\[18F\\]F-RESCA-RND20). ImmunoPET\u002FCT imaging will be acquired 1-2 hours after \\[18F\\]F-RESCA-RND20 injection.",[9],[84],"[18F]F-RND20",[86],{"name":87,"affiliation":88,"role":89},"Weijun Wei","Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University","STUDY_CHAIR",[91,97],{"name":92,"role":93,"phone":94,"phoneExt":95,"email":96},"Weijun Wei, Ph.D. & M.D.","CONTACT","15000083153",null,"wwei@shsmu.edu.cn",{"name":98,"role":93,"phone":99,"phoneExt":95,"email":100},"Shuxian An, Ph.D. & M.D.","17717453484","anshuxian@shsmu.edu.cn",[102],{"facility":103,"status":104,"city":105,"state":106,"zip":107,"country":108,"cosmosGeoPoint":109,"geoPoint":114,"contacts":115},"Renji Hospital, School of Medicine, Shanghai Jiao Tong University","RECRUITING","Shanghai","Shanghai Municipality","200127","China",{"type":110,"coordinates":111},"Point",[112,113],121.45806,31.22222,{"lat":113,"lon":112},[116,117],{"name":92,"role":93,"phone":94,"phoneExt":95,"email":96},{"name":98,"role":93,"phone":99,"phoneExt":95,"email":100},{"type":119,"investigatorFullName":95,"investigatorTitle":95,"investigatorAffiliation":95,"oldNameTitle":95,"oldOrganization":95},"SPONSOR","100571099",false,"NCT06715839","Target-specific immunoPET Imaging of Digestive System Carcinoma","Development and Clinical Translation of immunoPET Imaging Probes for Digestive System Carcinoma","Inclusion Criteria:\n\n1. Aged 18-75 years old and of either sex；\n2. Histologically confirmed diagnosis of digestive system carcinoma or suspected digestive system carcinoma by diagnostic imaging;\n3. Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.\n\nExclusion Criteria:\n\n1. Pregnancy；\n2. Severe hepatic and renal insufficiency;\n3. History of serious surgery in the last month;\n4. Allergic to antibody or single-domain antibody radiopharmaceuticals.","ALL","18 Years","75 Years",{"count":130,"type":131},400,"ESTIMATED","INTERVENTIONAL",[134],"NA","The aim of this study is to establish and optimize the target-specific PET\u002FCT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in digestive system malignant tumors will be evaluated.",[137,138,139,140,141,142,143,144,145,146,147,148,149,150,151],"Malignancy","Digestive Cancer","Digestive System Neoplasm","Digestive System Carcinoma","Digestive System Cancer","Liver Cancer","Stomach Cancer","Colon Cancer","Rectum Cancer","Pancreatic Cancer","Esophagus Cancer","Gallbladder Carcinoma","Small Intestine Cancer","Appendix Cancer","Bile Duct Carcinoma",[153,154,155,156,157],"human epidermal growth factor receptor 2 (HER2)","Trophoblast cell surface antigen 2 (TROP2)","Glypican-3 (GPC3)","Glycoprotein A33 (gpA33)","Nectin cell adhesion molecule-4 (Nectin-4)","2025-12-25",{"date":160,"type":161},"2025-12-31","ACTUAL",{"date":163,"type":161},"2024-12-04",{"date":165,"type":131},"2027-09",{"name":5,"class":6},1]